in seropositive patients, 52-week mean selena-sledai scores were decreased by 28.8% with belimumab versus 14.2% with placebo (p < 0.05), and physician's global assessment scores were improved by 32.7% with belimumab versus 10.7% with placebo (p < 0.05).